4-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid ethyl ester | 784193-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid ethyl ester
• 英文别名: ethyl 4-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)pyrazole-3-carboxylate
• CAS: 784193-06-2
• 化学式: C₁₈H₁₅Cl₂N₃O₂
• 分子量: 376.242
• InChiKey: JWYXVTRVWGYWFO-UHFFFAOYSA-N

物化性质

• 沸点：
  523.5±50.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid ethyl ester 在 caesium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-ethyl-2,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
  参考文献：
  名称：

  New bicyclic cannabinoid receptor-1 (CB1-R) antagonists

  摘要：

  A series of conformationally constrained bicyclic derivatives derived from SR141716 was prepared and evaluated as hCB(1)-R antagonists and inverse agonists. Optimization of the structure-activity relationships around the 2,6-dihydro-pyrazolo[4,3 -d]pyrimidin-7-one derivative 2a led to the identification of two compounds with oral activity in rodent feeding models (2h and 4a). Replacement of the PP group in 2h with other bicyclic groups resulted in a loss of binding affinity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.019
• 作为产物：
  描述：

  4-(4-chlorophenyl)-2-hydroxy-4-oxobut-2-enoic acid ethyl ester lithium salt 在 sodium dithionite 、 sodium nitrite 作用下， 以 溶剂黄146 、 乙酸乙酯 为溶剂， 生成 4-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  New bicyclic cannabinoid receptor-1 (CB1-R) antagonists

  摘要：

  A series of conformationally constrained bicyclic derivatives derived from SR141716 was prepared and evaluated as hCB(1)-R antagonists and inverse agonists. Optimization of the structure-activity relationships around the 2,6-dihydro-pyrazolo[4,3 -d]pyrimidin-7-one derivative 2a led to the identification of two compounds with oral activity in rodent feeding models (2h and 4a). Replacement of the PP group in 2h with other bicyclic groups resulted in a loss of binding affinity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.019

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc

  公开号：US20040214838A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
  申请人：Carpino A. Philip

  公开号：US20050101592A1

  公开（公告）日：2005-05-12

  Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.

  本文描述了化学式（I）的化合物。已经证明这些化合物可以作为大麻素受体配体，并且因此在治疗与动物体内大麻素受体介导相关的疾病方面是有用的。
• Cannabiniod receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US07141669B2

  公开（公告）日：2006-11-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein

  本文描述了公式（I）的化合物，其作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中的用途。
• CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Carpino A. Philip

  公开号：US20070105856A1

  公开（公告）日：2007-05-10

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了化学式（I）的化合物，它们作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中使用的方法。
• BICYCLIC PYRAZOLYL AND IMIDAZOLYL COMPOUNDS AND USES THEREOF
  申请人：Carpino A. Philip

  公开号：US20070027133A1

  公开（公告）日：2007-02-01

  Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.

  本文描述了公式（I）的化合物。这些化合物已被证明作为大麻素受体配体，并因此在治疗与动物中大麻素受体调节相关的疾病中具有用途。